Isolated perfusion of pancreas with mitomycin C.
The current treatment of pancreatic cancer with resection and/or radiation is considered unsatisfactory because of a high incidence of failure and a moderate incidence of complications. A sizable number of these patients present with localized or regional disease. Regional high-dose chemotherapy, such as with isolated perfusion, may offer an alternative therapy with low treatment-related morbidity and mortality and better end results in this group of patients. In an effort to develop such a treatment modality, we evaluated the pharmacokinetics and toxicity of mitomycin C (MMC) during isolated perfusion of pancreas in a canine model. From this study, it appears that a dose of 0.25 mg MMC/kg body weight is most suitable for isolated perfusion of pancreas at 39 degrees C, maintaining flow rate and pressure within physiologic range. Isolated perfusion with a dose of 0.25 mg/kg body weight has very mild short- and long-term toxicities and markedly increases drug delivery to the pancreas, duodenum, and peripancreatic lymph nodes, making it the most suitable dose for possible clinical application.
Arredondo
M A
MA
Department of Surgery, Medical College of Ohio, Toledo 43699-0008.
Chaudhuri
B
B
Kar
R
R
Crist
K A
KA
Thomford
N R
NR
Chaudhuri
P K
PK
D000681:Amylases / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D010478:Chemotherapy, Cancer, Regional Perfusion; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D004386:Duodenum / Q000378:metabolism; D007958:Leukocyte Count; D008049:Lipase / Q000097:blood; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D010179:Pancreas / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy
D001786:Blood Glucose; D008937:Mitomycins; D016685:Mitomycin; D008049:Lipase; D000681:Amylases